This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
F Artigas , A Adell , P Celada (2006). Pindolol augmentation of antidepressant response. Current Drug Targets 7, 139–147.
M-B Assié , L Bardin , R Depoortère , E Carilla-Durand , A Newman-Tancredi (2006 a). F15599, a highly selective serotonin 5-HT1A receptor agonist: in vivo profile in neurochemical and behavioural models of serotonergic activity. European Neuropsychopharmacology 16 (Suppl. 4), S233.
M-B Assié , H Lomenech , V Ravailhe , V Faucillon , (2006 b). Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat. British Journal of Pharmacology 149, 170–178.
HHG Berendsen , FGM Bourgondien , CLE Broekkamp (1994). Role of dorsal and median raphe nuclei in lower lip retraction in rats. European Journal of Pharmacology 263, 315–318.
HHG Berendsen , F Jenck , CL Broekkamp (1989). Selective activation of 5HT1A receptors induces lower lip retraction in the rat. Pharmacology, Biochemistry and Behavior 33, 821–827.
Z Bhagwagar , EA Rabiner , PA Sargent , PM Grasby , (2004). Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Molecular Psychiatry 9, 386–392.
KC Bicego , RC Barros , LG Branco (2007). Physiology of temperature regulation: comparative aspects. Comparative Biochemistry and Physiology, Part A 147, 616–639.
P Blier , NM Ward (2003). Is there a role for 5-HT1A agonists in the treatment of depression? Biological Psychiatry 53, 193–203.
J Buritova , G Berrichon , C Cathala , FC Colpaert , (2009). Region-specific changes in 5-HT1A agonist-induced extracellular signal-regulated kinases 1/2 phosphorylation in rat brain: a quantitative ELISA study. Neuropharmacology 56, 350–361.
AE Calogero , G Bagdy , K Szemeredi , ME Tartaglia , (1990). Mechanisms of serotonin receptor agonist-induced activation of the hypothalamic–pituitary–adrenal axis in the rat. Endocrinology 126, 1888–1894.
FC Colpaert , W Koek , J Lehmann , JM Rivet , (1992). S-14506 – a novel, potent, high-efficacy 5-HT1A agonist and potential anxiolytic agent. Drug Development Research 26, 21–48.
JC Compaan , L Groenink , J Van der Gugten , RAA Maes , (1997). Pretreatment with 5-HT1A receptor agonist flesinoxan attenuates Fos protein in rat hypothalamus. European Journal of Pharmacology 324, 161–168.
JF Cryan , P Kelliher , JP Kelly , BE Leonard (1999). Comparative effects of serotonergic agonists with varying efficacy at the 5-HT1A receptor on core body temperature: modification by the selective 5-HT1A receptor antagonist WAY 100635. Journal of Psychopharmacology 13, 278–283.
J De Vry (1995). 5-HT1A receptor agonists: recent developments and controversial issues. Psychopharmacology 121, 1–26.
J De Vry , R Schreiber (1993). Comparison of acute and repeated treatment with the 5-HT1A receptor ligands 8-OH-DPAT and ipsapirone in animal models of anxiety and depression. Drug Development Research 30, 91–103.
J De Vry , R Schreiber , C Melon , M Dalmus , (2004). 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat. European Neuropsychopharmacology 14, 487–495.
MJ Detke , S Wieland , I Lucki (1995). Blockade of the antidepressant-like effects of 8-OH-DPAT, buspirone and desipramine in the rat forced swim test by 5HT1A receptor antagonists. Psychopharmacology 119, 47–54.
WC Drevets , E Frank , JC Price , DJ Kupfer , (1999). PET imaging of serotonin 1A receptor binding in depression. Biological Psychiatry 46, 1375–1387.
M El Yacoubi , S Bouali , D Popa , L Naudon , (2003). Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proceedings of the National Academy of Sciences USA 100, 6227–6232.
L Groenink , J Van der Gugten , JC Compaan , RA Maes , (1997). Flesinoxan pretreatment differentially affects corticosterone, prolactin and behavioural responses to a flesinoxan challenge. Psychopharmacology 131, 93–100.
N Haddjeri , C Ortemann , C De Montigny , P Blier (1999). Effect of sustained administration of the 5-HT1A receptor agonist flesinoxan on rat 5-HT neurotransmission. European Neuropsychopharmacology 9, 427–440.
SA Julious (2004). Using confidence intervals around individual means to assess statistical significance between two means. Pharmaceutical Statistics 3, 217–222.
D Kelder , SB Ross (1992). Long lasting attenuation of 8-OH-DPAT-induced corticosterone secretion after a single injection of a 5-HT1A receptor agonist. Naunyn-Schmiedebergs Archives of Pharmacology 346, 121–126.
T Kenakin (2007). Functional selectivity through protean and biased agonism: who steers the ship? Molecular Pharmacology 72, 1393–1401.
W Koek , B Vacher , C Cosi , M-B Assié , (2001). 5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential. European Journal of Pharmacology 420, 103–112.
C Mannoury la Cour , S El Mestikawy , N Hanoun , M Hamon , (2006). Regional differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the rat brain. Molecular Pharmacology 70, 1013–1021.
GK Matheson , BU Raess , G Tunnicliff (1996). Effects of repeated doses of azapirones on rat brain 5-HT1A receptors and plasma corticosterone levels. General Pharmacology 27, 355–361.
JM Miller , KG Brennan , TR Ogden , MA Oquendo , (2009). Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality. Neuropsychopharmacology 34, 2275–2284.
MC Miquel , E Doucet , C Boni , S El Mestikawy , (1991). Central serotonin1A receptors – respective distributions of encoding messenger RNA, receptor protein and binding sites by in situ hybridization histochemistry, radioimmunohistochemistry and autoradiographic mapping in the rat brain. Neurochemistry International 19, 453–465.
L Naudon , M El Yacoubi , JM Vaugeois , I Leroux-Nicollet , (2002). A chronic treatment with fluoxetine decreases 5-HT1A receptors labeling in mice selected as a genetic model of helplessness. Brain Research 936, 68–75.
A Newman-Tancredi , JC Martel , M-B Assié , J Buritova , (2009). Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. British Journal of Pharmacology 156, 338–353.
RV Parsey , MA Oquendo , RT Ogden , DM Olvet , (2006). Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biological Psychiatry 59, 106–113.
C Sanchez (2003). Stress-induced vocalisation in adult animals. A valid model of anxiety? European Journal of Pharmacology 463, 133–143.
PA Sargent , KH Kjaer , CJ Bench , EA Rabiner , (2000). Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635 – effects of depression and antidepressant treatment. Archives of General Psychiatry 57, 174–180.
J Savitz , I Lucki , WC Drevets (2009). 5-HT1A receptor function in major depressive disorder. Progress in Neurobiology 88, 17–31.
J Shao , D Tu (1995). The Jackknife and Bootstrap. New York: Springer Verlag Inc.
GM Sullivan , RT Ogden , MA Oquendo , JS Kumar , (2009). Positron emission tomography quantification of serotonin-1. A receptor binding in medication-free bipolar depression. Biological Psychiatry 66, 223–230.
B Szewczyk , PR Albert , AM Burns , M Czesak , (2009). Gender-specific decrease in NUDR and 5-HT1A receptor proteins in the prefrontal cortex of subjects with major depressive disorder. International Journal of Neuropsychopharmacology 12, 155–168.
MD Tricklebank , C Forler , JR Fozard (1984). The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. European Journal of Pharmacology 106, 271–282.
S Wieland , I Lucki (1990). Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test. Psychopharmacology 101, 497–504.